AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2014
Jan 22, 2014
31580_dirs_2014-01-22_fe14b1cd-bcfe-467b-bd0d-72d58cd7e8c9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2014-01-21
Reporting Person: Goddard Glenn (Senior Vice President, Finance)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-01-21 | Common Stock | M | 10000 | $0.4675 | Acquired | 10000 | Direct |
| 2014-01-21 | Common Stock | S | 10000 | $34.7108 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-01-21 | Stock Option (right to buy) | $9.05 | A | 3636 | Acquired | 2023-04-29 | Common Stock (3636) | Direct |
| 2014-01-21 | Stock Option (right to buy) | $0.4675 | M | 10000 | Disposed | 2020-08-11 | Common Stock (10000) | Direct |
Footnotes
F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $32.82 to $36.29. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4: This option was granted on April 30, 2013 for the purchase of 14,545 shares of common stock. The option vests as to 25% of the underlying shares upon the achievement of a performance milestone, as to an additional 50% upon the achievement of a second performance milestone, and as to the remaining 25% on the first anniversary of the first date that both performance milestones were achieved. The performance criteria for the first performance milestone were met on January 21, 2014, resulting in the vesting of the option as to 3,636 shares.
F5: This option was granted on August 12, 2010. The shares underlying this option vest as to 25% of the underlying shares on July 1, 2011, with the remaining 75% vesting in 36 equal monthly installments thereafter.